BR0209290A - Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh - Google Patents

Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh

Info

Publication number
BR0209290A
BR0209290A BR0209290-5A BR0209290A BR0209290A BR 0209290 A BR0209290 A BR 0209290A BR 0209290 A BR0209290 A BR 0209290A BR 0209290 A BR0209290 A BR 0209290A
Authority
BR
Brazil
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
BR0209290-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BR0209290A publication Critical patent/BR0209290A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BR0209290-5A 2001-04-30 2002-04-27 Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh BR0209290A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (1)

Publication Number Publication Date
BR0209290A true BR0209290A (pt) 2004-07-13

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209290-5A BR0209290A (pt) 2001-04-30 2002-04-27 Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh

Country Status (27)

Country Link
US (1) US7288517B2 (enExample)
EP (1) EP1392348B1 (enExample)
JP (1) JP2004529207A (enExample)
KR (1) KR20040000446A (enExample)
CN (1) CN1317030C (enExample)
AT (1) ATE400287T1 (enExample)
AU (1) AU2002310788B2 (enExample)
BG (1) BG108339A (enExample)
BR (1) BR0209290A (enExample)
CA (1) CA2444876A1 (enExample)
CZ (1) CZ20033167A3 (enExample)
DE (1) DE60227507D1 (enExample)
DK (1) DK1392348T3 (enExample)
ES (1) ES2307760T3 (enExample)
HU (1) HUP0400067A2 (enExample)
IL (1) IL156777A0 (enExample)
MX (1) MXPA03008666A (enExample)
NO (1) NO20034322L (enExample)
NZ (1) NZ544417A (enExample)
PL (1) PL362319A1 (enExample)
PT (1) PT1392348E (enExample)
RU (1) RU2319501C2 (enExample)
SI (1) SI1392348T1 (enExample)
SK (1) SK14512003A3 (enExample)
UA (1) UA80679C2 (enExample)
WO (1) WO2002102401A1 (enExample)
ZA (1) ZA200305326B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
PT1300398E (pt) 2000-07-05 2006-07-31 Astellas Pharma Inc Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
MXPA06014131A (es) * 2004-06-04 2007-03-07 Astellas Pharma Inc Derivado de propano-1,3-diona o su sal.
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
SI1864976T1 (sl) * 2005-03-31 2012-12-31 Astellas Pharma Inc. Propan-1,3-dionski derivat ali njegova sol
WO2008046919A2 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
AU2008303928A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection
AU2008306264A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
CA2254769A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
EP1185530A1 (en) 1999-05-14 2002-03-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
MXPA02003614A (es) 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
US20030134863A1 (en) 2000-04-13 2003-07-17 Shuichi Furuya Preventives/remedies for alzheimer's disease
PT1300398E (pt) * 2000-07-05 2006-07-31 Astellas Pharma Inc Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta

Also Published As

Publication number Publication date
NO20034322D0 (no) 2003-09-26
EP1392348B1 (en) 2008-07-09
ZA200305326B (en) 2003-07-30
JP2004529207A (ja) 2004-09-24
SI1392348T1 (sl) 2008-12-31
RU2003134949A (ru) 2005-02-10
IL156777A0 (en) 2004-02-08
US7288517B2 (en) 2007-10-30
RU2319501C2 (ru) 2008-03-20
NZ544417A (en) 2008-03-28
CN1575185A (zh) 2005-02-02
SK14512003A3 (sk) 2004-08-03
DE60227507D1 (de) 2008-08-21
HK1072000A1 (en) 2005-08-12
PL362319A1 (en) 2004-10-18
CZ20033167A3 (cs) 2004-08-18
US20020177556A1 (en) 2002-11-28
DK1392348T3 (da) 2008-09-29
BG108339A (bg) 2004-11-30
PT1392348E (pt) 2008-09-09
HUP0400067A2 (hu) 2004-04-28
NO20034322L (no) 2003-09-26
MXPA03008666A (es) 2004-10-15
AU2002310788B2 (en) 2007-04-05
KR20040000446A (ko) 2004-01-03
CN1317030C (zh) 2007-05-23
WO2002102401A1 (en) 2002-12-27
ATE400287T1 (de) 2008-07-15
CA2444876A1 (en) 2002-12-27
EP1392348A1 (en) 2004-03-03
ES2307760T3 (es) 2008-12-01
UA80679C2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
IL156777A0 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR0016022A (pt) Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
NO20071560L (no) Vasopressin v1a-antagonister.
GB0129260D0 (en) Pharmaceutical compositions and their uses
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0307998A (pt) Hidroxietilaminas substituìdas
BR9408063A (pt) Antagonistas de receptores de taquicinina que nÆo sÆo pept¡deos
GB0223040D0 (en) Therapeutic compounds
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0206495A (pt) Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
MA28106A1 (fr) Compositions immunogenes
BR0110383A (pt) Peptìdeo modulador de receptor de trombopoietina
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
PL1626726T3 (pl) Zastosowanie lornoksykamu lub analogów lornoksykamu
ATE397755T1 (de) Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
WO2003090771A3 (en) Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.